Last reviewed · How we verify
GM102 escalating doses
At a glance
| Generic name | GM102 escalating doses |
|---|---|
| Sponsor | GamaMabs Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GM102 escalating doses CI brief — competitive landscape report
- GM102 escalating doses updates RSS · CI watch RSS
- GamaMabs Pharma portfolio CI